[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100616476":3},{"organization":4,"armGroups":7,"interventions":28,"overallOfficials":38,"centralContacts":42,"locations":50,"responsibleParty":90,"collaborators":92,"id":97,"slug":24,"hasResults":98,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":24,"eligibilityCriteria":102,"healthyVolunteers":103,"sex":104,"minAge":105,"maxAge":24,"enrollmentInfo":106,"targetDuration":24,"studyType":109,"phases":110,"briefSummary":112,"conditions":113,"keywords":115,"overallStatus":53,"whyStopped":24,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":126},{"fullName":5,"class":6},"University of Southern Denmark","OTHER",[8,14,20,25],{"label":9,"type":10,"description":11,"interventionNames":12},"Intervention group 1: Full T-PEMF","EXPERIMENTAL","Persons with Parkinson's disease receiving 30 min daily active T-PEMF for 12 months. The first 6 months are blinded, the last 6 months are not.",[13],"Device: Transcranial pulsed electromagnetic fields (T-PEMF)",{"label":15,"type":16,"description":17,"interventionNames":18},"Intervention group 2: sham + T-PEMF","SHAM_COMPARATOR","Persons with Parkinson's disease receiving 30 min daily sham T-PEMF for 6 months followed by 6 moths of 30 min daily active T-PEMF. The first 6 month is blinded, the last 6 months are not.",[13,19],"Device: Sham (No Treatment)",{"label":21,"type":22,"description":23,"interventionNames":24},"Control group","NO_INTERVENTION","Persons with Parkinson's disease receiving no experimental treatment. The group is used to monitor natural course of the disease.",null,{"label":26,"type":22,"description":27,"interventionNames":24},"Healthy reference group","Health age-matched persons assessed once to obtain age-matched normal intervals of performance.",[29,34],{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":24},"DEVICE","Transcranial pulsed electromagnetic fields (T-PEMF)","30 min daily stimulation with transcranial pulsed electromagnetic fields (50 Hz)",[9,15],{"type":30,"name":35,"description":36,"armGroupLabels":37,"otherNames":24},"Sham (No Treatment)","30 min daily the participants are using\u002Fwearing the T-PEMF device but no stimulation occurs",[15],[39],{"name":40,"affiliation":5,"role":41},"Anne Sofie Bøgh Malling, Ph.d.","PRINCIPAL_INVESTIGATOR",[43,47],{"name":40,"role":44,"phone":45,"phoneExt":24,"email":46},"CONTACT","+45 28903733","amalling@health.sdu.dk",{"name":48,"role":44,"phone":24,"phoneExt":24,"email":49},"Bente Rona Jensen, Professor","brjensen@health.sdu.dk",[51,69],{"facility":52,"status":53,"city":54,"state":24,"zip":55,"country":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":63},"Odense University Hospital","RECRUITING","Odense","5000","Denmark",{"type":58,"coordinates":59},"Point",[60,61],10.38831,55.39594,{"lat":61,"lon":60},[64,68],{"name":65,"role":44,"phone":66,"phoneExt":24,"email":67},"Christian Winterberg, MD","+45 65411833","christian.winterberg@rsyd.dk",{"name":65,"role":41,"phone":24,"phoneExt":24,"email":24},{"facility":5,"status":53,"city":54,"state":24,"zip":70,"country":56,"cosmosGeoPoint":71,"geoPoint":73,"contacts":74},"5230",{"type":58,"coordinates":72},[60,61],{"lat":61,"lon":60},[75,76,79,81,84,86,88],{"name":40,"role":44,"phone":45,"phoneExt":24,"email":46},{"name":77,"role":44,"phone":24,"phoneExt":24,"email":78},"Jens Bojsen-Møller, Ass. proffessor","jbojsen@health.sdu.dk",{"name":80,"role":41,"phone":24,"phoneExt":24,"email":24},"Anne Sofie B Malling, Ph.d.",{"name":82,"role":83,"phone":24,"phoneExt":24,"email":24},"Mikkel C Juhl, MSc","SUB_INVESTIGATOR",{"name":85,"role":83,"phone":24,"phoneExt":24,"email":24},"Morten Meyer, Professor",{"name":87,"role":83,"phone":24,"phoneExt":24,"email":24},"Bente R Jensen, Professor",{"name":89,"role":83,"phone":24,"phoneExt":24,"email":24},"Jens Bojsen-Møller, Ass. Professor",{"type":91,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR",[93,94],{"name":52,"class":6},{"name":95,"class":96},"Bente & Erik Schøller Larsens Foundation","UNKNOWN","100616476",false,"NCT07306104","The Effect of Long-term Daily Stimulation of the Brain With Pulsed Electromagnetic Fields on Parkinsons Disease","The Effect of Long-term Treatment of Parkinson's Disease With T-PEMF","Intervention Groups\n\nInclusion Criteria:\n\n* Diagnosed with idiopathic Parkinson's disease\n* The participant must be able to understand, accept, and complete the planned procedures\n* Parkinson's symptoms in the medicated state must correspond to Hoehn \\& Yahr stage 1 or 2\n* Mini Mental-State Examination score \\> 22\n\nExclusion Criteria:\n\n* Cancer in the brain, neck, or head area\n* Presence of active medical implants\n* Epilepsy\n* Alcoholism\n* Substance abuse\n* Open wound on the scalp\n* Severe psychopathological disorders\n* Pregnancy\n* Changes in pharmacological anti-Parkinson medication within the last 6 weeks prior to the start of T-PEMF treatment\n* Anticoagulant treatment with Marevan, Marcoumar, Pradaxa, Eliquis, Xarelto, Lixiana, Novostan, Fragmin, or Innohep\n* Neurological disease other than Parkinson's disease\n* Previous stroke\n* Reduced motor function caused by conditions other than Parkinson's disease\n\nControl Group with Parkinson's Disease\n\nInclusion Criteria:\n\n* Diagnosed with idiopathic Parkinson's disease\n* The patient must be able to understand, accept, and complete the planned procedures\n* Parkinson's symptoms in the medicated state must correspond to Hoehn \\& Yahr stage 1 or 2\n* Mini Mental-State Examination score \\> 22\n\nExclusion Criteria:\n\n* Neurological disease other than Parkinson's disease\n* Reduced motor function caused by conditions other than Parkinson's disease\n\nHealthy Reference Group:\n\nInclusion Criteria:\n\n-The patient must be able to understand, accept, and complete the planned procedures\n\nExclusion Criteria:\n\n* Neurological disease\n* Reduced motor function caused by condition",true,"ALL","18 Years",{"count":107,"type":108},90,"ESTIMATED","INTERVENTIONAL",[111],"NA","The goal of this clinical trial is to learn to what extent daily stimulation of the brain with transcranial pulsed electromagnetic fields (T-PEMF) works to treat persons with Parkinson's Disease. The main questions it aims to answer are:\n\n* How does 6 months of daily treatment (30 minutes\u002Fday) with T-PEMF affects neuro-mechanical and molecular biological factors compared with placebo treatment in persons with Parkinson's disease?\n* How does 12 months of daily treatment (30 minutes\u002Fday) with T-PEMF affects neuro-mechanical and molecular biological factors in persons with Parkinson's disease an does 12 months of T-PEMF alters the need for medication intake?\n\nThe neuro-mechanical outcomes are compared with the \"natural\" progression of the disease as well as with a healthy reference group. Furthermore, it will be examined whether 12 months of T-PEMF treatment alters the need for medication intake.\n\nParticipants in the intervention group will:\n\n* receive one 30 min treatment session daily for 12 months\n* receive either T-PEMF or sham treatment for the first 6 months\n* receive active T-PEMF treatment the last 6 months\n* visit for tests before treatment initiation, after 6 months of treatment and after 12 months of treatment.",[114],"PARKINSON DISEASE (Disorder)",[116],"T-PEMF","2026-04-28",{"date":119,"type":120},"2026-04-29","ACTUAL",{"date":122,"type":120},"2026-02-16",{"date":124,"type":108},"2028-01",{"name":5,"class":6},2]